SPY420.86+5.94 1.43%
DIA338.78+5.82 1.75%
IXIC14,141.48+111.10 0.79%

Incyte, MorphoSys Dose First Patient in Late-Stage Study of Lymphoma Drug Candidate

05/12/2021 02:10

06:01 AM EDT, 05/12/2021 (MT Newswires) -- Incyte (INCY) and partner MorphoSys (MOR) said Tuesday they have dosed the first patient in their phase 3 study evaluating a regimen as a first-line treatment for B-cell lymphoma.

The phase 3 trial, called frontMIND, is expected to enroll about 880 patients. The primary endpoint is progression-free survival, while secondary endpoints include overall survival and metabolic complete response rate.

Price: 80.64, Change: -0.75, Percent Change: -0.92